Close Menu

More articles about Tools & Technology

Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.

Researchers found that TP53 mutations correlated with improved disease-free survival and overall survival in pancreatic cancer patients treated with gemcitabine following surgical resection.

A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.

An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.

Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.

The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.

Researchers will use the VCurePrecision EMR platform to improve understanding of cancer, and doctors can use it make care decisions for patients.

With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.

The analysis also suggested ways to outwit these mechanisms based on the degree of immune cell infiltration into the tumor. 

Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

The Angiosarcoma Project uses patient-partnered research to gather information and glean new genomic insights into angiosarcomas.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.

Paired tumor/germline analysis is not routinely done in cancer care, but some labs are starting to report incidental germline findings alongside patient's tumor profiles.

Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.

Pages